SCHEMBL24461631

SCHEMBL24461631

Cc1c(C2CCN(C(=O)OC(C)(C)C)CC2)[nH]c2nnc(Cl)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ JAK2 O60674 1/20 0.46
▸ JAK1 P23458 1/20 0.46
▸ TYK2 P29597 1/20 0.46
▸ JAK3 P52333 1/20 0.46
▸ STS P08842 3/20 0.42
▸ TP53 P04637 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619438 1.00 CNR1 (0.48) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL24461562 0.85 MAPT (0.47) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL24461526 0.82 SMARCA2 (0.53) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL29619399 0.82 SMARCA2 (0.53) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL29619377 0.78 KDM4E (0.39) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL24461356 0.78 KDM4E (0.39) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL26683361 0.77 MAPT (0.44) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL30666276 0.77 MAPT (0.44) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL31424848 0.75 ESR2 (0.40) CNR1MAPTKDM4ETHRBJAK2
SCHEMBL30658028 0.74 MAPT (0.54) CNR1MAPTKDM4ETHRBJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 — — US disclosed
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 — — US disclosed
CN-116744929-A Compounds and uses thereof 福霍恩治疗公司 2023-09-12 — — CN disclosed
WO-2022109426-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024488-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CNR1 4168/4885MAPT 2074/4885KDM4E 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback